Last Updated: 2012-07-23 11:15:06 -0400 (Reuters Health)
By Tan Ee Lyn
HONG KONG (Reuters) - Breast cancer cells can shut down a powerful immune response in the body, which allows the disease to spread to the patient's bones, researchers in Australia reported on Monday.
They also experimented with two ways to reinstate this immune response to help patients fight breast cancer, but it will take more tests and several more years for these therapies to become routine treatments, they said.
"We have identified a way that breast cancer cells can turn off the immune system, allowing them to spread to distant parts such as the bone," said the study's senior author Belinda Parker, a research fellow at the Peter MacCallum Cancer Centre in Melbourne.
"By understanding how this occurs, we hope to use existing and new therapies to restore this immune function and prevent the spread of cancer," she said by telephone.
The study was published Monday in the journal Nature Medicine.
In 2010, 1.5 million people worldwide were diagnosed with breast cancer, the most common cancer in women.
Although it kills many women in developing countries, 89 percent of women diagnosed with breast cancer in western countries are still alive five years after diagnosis thanks to early detection and treatment.
Using tissue samples from breast cancer patients and experiments with mice, Parker and colleagues found that a gene called IRF7 is switched off in patients whose cancer spreads to other parts of the body.
IRF7 controls the production of interferon, an important immune signaling protein that fights viruses and bacteria apart from tumor cells
"Usually when breast cancer cells leave the breast and travel in the bloodstream and into bone marrow, the release of interferons by IRF7 will cause the immune system to recognize those cells and eliminate them," Parker said.
"But by losing IRF7, it prevents the stimulation of immune responses and allows those cells to hide from being recognized (and later spread)."
Parker and her team tried two ways to revive this immune response in experiments with mice and both appeared to work.
"We put the gene back into cancer cells so it can't switch it (IRF7) off. We allowed the immune pathway to be stimulated and the cancer cells did not spread to the bone," Parker said.
"The other way is to treat the animals with interferon, which is available for treating other diseases, like hepatitis. That also prevented the spread of cancer to the bone."
Parker said they will study how best to use these two methods on patients in the next few years and plan to have a clinical trial in two to three years.
SOURCE: http://bit.ly/Oj3XZ2 Nature Medicine, online July 22, 2010.
Copyright © 2012 Reuters Limited. All rights reserved.Republication or redistribution of Reuters content, including by framing orsimilar means, is expressly prohibited without the prior written consent ofReuters. Reuters shall not be liable for any errors or delays in thecontent, or for any actions taken in reliance thereon.Reuters and the Reuters sphere logo are registered trademarks andtrademarks of the Reuters group of companies around the world.